TransCode Therapeutics, Inc. Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer
September 23, 2021 at 07:30 am EDT
Share
TransCode Therapeutics, Inc. announced that preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. The article, entitled Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastic lesions in a murine model of metastatic breast cancer, resulted from research conducted at the Athinoula A. Martinos Center for Biomedical Imaging in the Department of Radiology at Massachusetts General Hospital and Harvard Medical School. This preclinical study developed a radio-labeled derivative of TTX-MC138 (referenced as MN-anti-miR10b) tagged with Cu-64, enabling highly sensitive and specific quantitative determination of its pharmacokinetics and biodistribution, as well as observation of delivery to metastases via noninvasive positron emission tomography-magnetic resonance imaging (PET-MRI). The key results of the study demonstrated that TTX-MC138, when injected intravenously, accumulated in metastatic lesions. These results suggest that TransCode’s TTX platform delivers its therapeutic candidate as intended and the company believes supports clinical evaluation of TTX-MC138. In addition, the investigation describes the development of a microdosing PET-MRI approach that could potentially be used for measurement of TTX-MC138 biodistribution in cancer patients and its delivery to clinical metastases. The capacity to carry out microdosing PET studies in patients under an exploratory investigational new drug application protocol would represent an important step on the path to clinical translation because it could facilitate and expedite approval from the U.S. Food and Drug Administration (FDA) for initial human studies. TransCode expects to file an exploratory investigational new drug (eIND) application for TTX-MC138 in the first quarter of 2022 to support a Phase 0 study in patients with metastatic cancer. Under an eIND, FDA approval may be obtained more quickly and at lower cost than with a traditional IND for therapeutic agents.
TransCode Therapeutics, Inc. is a ribonucleic acid (RNA) oncology company. Its lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. Its preclinical programs include two solid tumor programs, TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. It also has two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment, and TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells, as well as TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines that are designed to activate cytotoxic immune responses.
TransCode Therapeutics, Inc. Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer
TRANSCODE THERAPEUTICS, INC. 
